Evidence map›Paper›PMID 32954246›Full record

ArticleSurgery open science2020

Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature.

Michael Johannes Pflüger, Matthäus Felsenstein, Ryan Schmocker, Laura DeLong Wood, Ralph Hruban, Kohei Fujikura, Noah Rozich, Floortje van Oosten, Matthew Weiss, William Burns and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery open science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Michael Johannes PflügerJohns Hopkins School of Medicine, Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Baltimore, MD, USA.
Matthäus FelsensteinJohns Hopkins School of Medicine, Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Baltimore, MD, USA.
Ryan SchmockerJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Laura DeLong WoodJohns Hopkins School of Medicine, Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Baltimore, MD, USA.
Ralph HrubanJohns Hopkins School of Medicine, Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Baltimore, MD, USA.
Kohei FujikuraJohns Hopkins School of Medicine, Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Baltimore, MD, USA.
Noah RozichJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Floortje van OostenJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Matthew WeissJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
William BurnsJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Jun YuJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
John CameronJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Johann PratschkeCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery (CCM/CVK), Berlin, Germany.
Christopher Lee WolfgangJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Jin HeJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Richard Andrew BurkhartJohns Hopkins Hospital, Department of Surgery, Hepatobiliary and Pancreatic Surgery Section of the Division of Surgical Oncology, Baltimore, MD, USA.
Johns Hopkins Hospital · USCancer Research Center · USJohns Hopkins University · USFreie Universität Berlin · DEHumboldt-Universität zu Berlin · DE

Funding

Personalized preclinical models in pancreas cancer: a tractable approach to precision medicineK08CA248710 · NCI · JOHNS HOPKINS UNIVERSITY · PI BURKHART, RICHARD ANDREW · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA248710
6 · The paper itself

Abstract

backgroundProlonged survival of patients after pancreaticoduodenectomy can be associated with late complications due to altered gastrointestinal anatomy. The incidence of gastric cancer is increasingly reported. We set out to examine our experience with gastric cancer as a late complication after pancreaticoduodenectomy with a focus on incidence, risk factors, and outcomes.

methodsWe queried our prospectively collected institutional database for patients that developed gastric cancer after pancreaticoduodenectomy and conducted a systematic review of the literature.

resultsOur database revealed 6 patients who developed gastric cancer following pancreaticoduodenectomy, presenting with a mean age of 62.2 years and an even sex distribution. All of those patients underwent pancreaticoduodenectomy for malignant indications with an average time to development of metachronous gastric cancer of 8.3 years. Four patients complained of gastrointestinal discomfort prior to diagnosis of secondary malignancy. All of these cancers were poorly differentiated and were discovered at an advanced T stage (≥ 3). Only half developed at the gastrointestinal anastomosis. Four underwent surgery with a curative intent, and 2 patients are currently alive (mean postgastrectomy survival = 25.5 months). In accordance with previous literature, biliopancreatic reflux from pancreaticoduodenectomy reconstruction, underlying genetic susceptibility, and adjuvant therapy may play a causative role in later development of gastric cancer.

conclusionLong-term survivors after pancreaticoduodenectomy who develop nonspecific gastrointestinal complaints should be evaluated carefully for complications including gastric malignancy. This may serve as an opportunity to intervene on tumors that typically present at an advanced stage and with aggressive histology.

Identifiers

PMID32954246
PMCPMC7486455
OpenAlexW3049694835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.